Shire merger with Baxalta completed.

Shire plc completed its previously announced combination with Baxalta Incorporated creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit compound annual top-line growth, with over $20 billion in annual projected revenue by 2020 and approximately 65% of total annual revenues being immediately generated by its rare disease products. Shire now has more than 50 programs in clinical development, with a balanced mix of early, mid and late-stage projects. With over 22,000 employees across more than 100 countries, Shire�s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs. Baxalta became an indirect wholly-owned subsidiary of Shire.